Hims & Hers Health, Inc.

Hims & Hers Health, Inc. (NYSE: HIMS) operates a consumer-first digital health and wellness platform that transforms how customers access routine medical care and health products. Founded in 2017, the company has facilitated over fifty million telehealth consultations across the United States, Canada, the United Kingdom, and the European Union, including Germany, Ireland, France, and Spain. The company's website is www.himshers.com.

The platform provides access to licensed healthcare professionals who deliver personalized treatment plans for chronic conditions including sexual health, hair loss, hormone health, weight loss, dermatology, and mental health. Hims & Hers also offers comprehensive laboratory testing services and a range of non-prescription health and wellness products. The company's integrated technology infrastructure includes an electronic medical record system, digital prescription capabilities, cloud pharmacy fulfillment, and proprietary personalization algorithms designed to support both patients and clinicians.

The business model centers on subscription-based recurring revenue, allowing customers to select shipment cadences ranging from every thirty days to annually. The company operates wholly-owned pharmacies including two licensed 503A pharmacies, two UK General Pharmaceutical Council-licensed pharmacies, a 503B compounding outsourcing facility, a peptide manufacturing facility, and a laboratory testing services facility. These integrated operations enable seamless drug delivery, supply chain oversight, and increased operating leverage while reducing costs typically associated with third-party pharmacy relationships.

Due to corporate practice of medicine restrictions in most U.S. states, Hims & Hers contracts with separate Affiliated Medical Groups owned by physicians to provide clinical services rather than directly employing providers. In the United Kingdom and Ireland, where no such restrictions exist, the company directly employs physicians through its subsidiaries. The company maintains partnerships with leading health systems and operates established retail partnerships in the United Kingdom through Asda and Superdrug.

The company's growth strategy focuses on acquiring new customers through omnichannel marketing, expanding within its existing customer base, launching new specialty offerings, leveraging its integrated pharmacy and laboratory capabilities, and expanding internationally. In February 2026, Hims & Hers announced a definitive agreement to acquire Eucalyptus, an Australia-based digital health company operating across multiple geographies.